Literature DB >> 24590511

HIV-associated multicentric Castleman's disease after initiation of antiretroviral therapy: experience of a European centre.

J Katchanov1, U Zimmermann, G Branding, K Arastéh, M Müller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590511     DOI： 10.1007/s15010-014-0605-5

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  8 in total

1.  An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS.

Authors:  C Zietz; J R Bogner; F D Goebel; U Löhrs
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

2.  Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman's disease.

Authors:  Siow Ming Lee; Simon G Edwards; Daniella N Chilton; Alan Ramsay; Robert F Miller
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

3.  How I treat HIV-associated multicentric Castleman disease.

Authors:  Mark Bower
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

Review 4.  Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.

Authors:  Stephen D Lawn; Graeme Meintjes
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

5.  Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.

Authors:  Christian Hoffmann; Holger Schmid; Markus Müller; Christian Teutsch; Jan van Lunzen; Stefan Esser; Timo Wolf; Christoph Wyen; Michael Sabranski; Heinz-August Horst; Stefan Reuter; Martin Vogel; Hans Jäger; Johannes Bogner; Keikawus Arasteh
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

6.  The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.

Authors:  T Powles; J Stebbing; A Bazeos; E Hatzimichael; S Mandalia; M Nelson; B Gazzard; M Bower
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

7.  Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.

Authors:  Lewis J Haddow; Robert Colebunders; Graeme Meintjes; Stephen D Lawn; Julian H Elliott; Yukari C Manabe; Paul R Bohjanen; Somnuek Sungkanuparph; Philippa J Easterbrook; Martyn A French; David R Boulware
Journal:  Lancet Infect Dis       Date:  2010-11       Impact factor: 25.071

8.  Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.

Authors:  Emilio Letang; James J Lewis; Mark Bower; Anisa Mosam; Margareth Borok; Thomas B Campbell; Denise Naniche; Tom Newsom-Davis; Fahmida Shaik; Suzanne Fiorillo; Jose M Miro; David Schellenberg; Philippa J Easterbrook
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.